Keros Therapeutics (KROS) Accumulated Expenses: 2019-2025
Historic Accumulated Expenses for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to $15.2 million.
- Keros Therapeutics' Accumulated Expenses fell 31.55% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year decrease of 31.55%. This contributed to the annual value of $20.9 million for FY2024, which is 16.48% up from last year.
- As of Q3 2025, Keros Therapeutics' Accumulated Expenses stood at $15.2 million, which was down 23.99% from $20.0 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Accumulated Expenses ranged from a high of $22.2 million in Q3 2024 and a low of $5.5 million during Q1 2021.
- In the last 3 years, Keros Therapeutics' Accumulated Expenses had a median value of $15.2 million in 2025 and averaged $15.9 million.
- In the last 5 years, Keros Therapeutics' Accumulated Expenses spiked by 87.71% in 2021 and then plummeted by 31.55% in 2025.
- Keros Therapeutics' Accumulated Expenses (Quarterly) stood at $7.3 million in 2021, then skyrocketed by 73.77% to $12.8 million in 2022, then spiked by 40.50% to $17.9 million in 2023, then rose by 16.48% to $20.9 million in 2024, then plummeted by 31.55% to $15.2 million in 2025.
- Its Accumulated Expenses stands at $15.2 million for Q3 2025, versus $20.0 million for Q2 2025 and $17.3 million for Q1 2025.